CYP2C19*17 is associated with decreased breast cancer risk

[1]  T. Illig,et al.  The CYP1B1_1358_GG genotype is associated with estrogen receptor-negative breast cancer , 2008, Breast Cancer Research and Treatment.

[2]  Wolfgang Simon,et al.  Breast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 genotypes. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  K. Ickstadt,et al.  Breast cancer: a candidate gene approach across the estrogen metabolic pathway , 2007, Breast Cancer Research and Treatment.

[4]  M. Dowsett,et al.  The relationship between factors affecting endogenous oestradiol levels in postmenopausal women and breast cancer , 2006, The Journal of Steroid Biochemistry and Molecular Biology.

[5]  T. Starzynska,et al.  Effect of CYP2C19*17 gene variant on Helicobacter pylori eradication in peptic ulcer patients , 2006, European Journal of Clinical Pharmacology.

[6]  T. Saleh,et al.  Role of Polymorphic Human Cytochrome P450 Enzymes in Estrone Oxidation , 2006, Cancer Epidemiology Biomarkers & Prevention.

[7]  Leif Bertilsson,et al.  A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants , 2006, Clinical pharmacology and therapeutics.

[8]  Mark Daly,et al.  Haploview: analysis and visualization of LD and haplotype maps , 2005, Bioinform..

[9]  H. Brauch,et al.  Factors Modifying the Association Between Hormone-Replacement Therapy and Breast Cancer Risk , 2005, European Journal of Epidemiology.

[10]  Thomas Brüning,et al.  ERCC2 genotypes and a corresponding haplotype are linked with breast cancer risk in a German population. , 2004, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[11]  Kyoichi Ohashi,et al.  Pharmacogenomics of proton pump inhibitors. , 2004, Pharmacogenomics.

[12]  J Licinio,et al.  Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response , 2004, Molecular Psychiatry.

[13]  P. Crosignani.  Breast cancer and hormone-replacement therapy in the Million Women Study. , 2003, Maturitas.

[14]  Valerie Beral,et al.  Breast cancer and hormone-replacement therapy in the Million Women Study , 2003, The Lancet.

[15]  T. Koike,et al.  The effects of lansoprazole on erosive reflux oesophagitis are influenced by CYP2C19 polymorphism , 2003, Alimentary pharmacology & therapeutics.

[16]  K. Ohashi,et al.  Effect of cytochrome P4502C19 genotypic differences on cure rates for gastroesophageal reflux disease by lansoprazole , 2002, Clinical pharmacology and therapeutics.

[17]  T. Key,et al.  The effect of diet on risk of cancer , 2002, The Lancet.

[18]  Charles Kooperberg,et al.  Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. , 2002, JAMA.

[19]  H. Zhou,et al.  Role of cytochrome P450 in estradiol metabolism in vitro. , 2001, Acta pharmacologica Sinica.

[20]  G. Morgan,et al.  Poor metabolizers at the cytochrome P450 2D6 and 2C19 loci are at increased risk of developing adult acute leukaemia. , 2000, Pharmacogenetics.

[21]  P. Wedlund.  The CYP2C19 Enzyme Polymorphism , 2000, Pharmacology.

[22]  Kyoichi Ohashi,et al.  Effect of Genetic Differences in Omeprazole Metabolism on Cure Rates for Helicobacter pylori Infection and Peptic Ulcer , 1998, Annals of Internal Medicine.

[23]  Hong-Guang Xie,et al.  Genetic analysis of the S‐mephenytoin polymorphism in a chinese population , 1995, Clinical pharmacology and therapeutics.

[24]  G R Wilkinson,et al.  Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese. , 1994, Molecular pharmacology.